Efficacy of adjuvant combination therapy with trastuzumab and chemotherapy in HER2-positive early breast cancer: A single institutional cohort study from clinical practice

Masahiro Okamoto, Wakako Tajiri, Hiroki Ueo, Takanobu Masuda, Hideki Ijichi, Chinami Koga, Yoshiaki Nakamura, Kenichi Taguchi, Shinji Ohno, Eriko Tokunaga

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background/Aim: To evaluate the improvement in the prognosis by adjuvant trastuzumab in clinical practice and the risk factors for distant recurrence, we retrospectively investigated the prognosis of HER2-positive early breast cancer in our department before and after the introduction of adjuvant trastuzumab. Patients and Methods: Cohorts A and B included 161 and 182 cases, respectively, who underwent surgery before (2000-2007) and after (2008-2015) the introduction of adjuvant trastuzumab. Results: The rates of relapse-free and distant metastasis-free survival were significantly better in cohort B than in cohort A. The risk factors of distant recurrence found in cohort A, such as the presence of lymph node metastasis, lymphatic invasion, and a low histological grade, did not increase the risk in cohort B. Conclusion: Many risk factors seemed to have been negated by adjuvant trastuzumab administration. Therefore, further escalation of adjuvant treatment should be carefully considered.

Original languageEnglish
Pages (from-to)3315-3323
Number of pages9
JournalAnticancer research
Volume40
Issue number6
DOIs
Publication statusPublished - Jun 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Efficacy of adjuvant combination therapy with trastuzumab and chemotherapy in HER2-positive early breast cancer: A single institutional cohort study from clinical practice'. Together they form a unique fingerprint.

Cite this